A comprehensive view of Horizon Therapeutics Plc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Horizon Therapeutics reports Phase 3 trial shows Uplizna inebilizumab-cdon injectable effective for patients with neuromyelitis optica spectrum disorder after one attack; NMOSD most common in women, people of African, Asian descent
Published: April 06, 2022 by Horizon Therapeutics Plc.
Horizon Therapeutics announces FDA has granted priority review of license application for Krystexxa pegloticase injection plus methotrexate to treat uncontrolled gout; Krystexxa is only approved biologic treatment for gout
Published: March 16, 2022 by Horizon Therapeutics Plc.
Ireland's Horizon Therapeutics submits supplemental biologics license application to US FDA for KRYSTEXXA, or pegloticase injection, with methotrexate for adults with uncontrolled gout; submission based on randomized trial data showing 71% response rate
Published: January 13, 2022 by Horizon Therapeutics Plc.

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count